Inherited retinal diseases such as Usher syndrome and Stargardt disease remain difficult to treat, particularly when the genes involved are too large for c...
Developing effective drug formulations remains a major challenge for biopharma companies, particularly for molecules with poor solubility or complex releas...
Bringing microbiome-based therapies to patients requires more than promising clinical results. Manufacturing complex mixtures of live bacteria consistently...
For people living with hereditary angioedema (HAE), sudden and unpredictable swelling attacks can disrupt daily life and require urgent treatment. Pharva...
For patients living with inflammatory bowel disease (IBD), persistent symptoms, repeated treatment failures and the need for lifelong therapy remain major ...
For military personnel and veterans diagnosed with cancer, accessing specialised testing and treatment options can be difficult, particularly when care...
For millions of women living with endometriosis, persistent pain can disrupt daily life, affect fertility and limit treatment choices. Existing hormonal th...
Ambrose Healthcare’s acquisition of AM-Pharma, valued at up to €161 million plus royalties, strengthens its rare disease pipeline and establishe...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
Biopharma Boardroom speaks with Quentin Le Masne de Chermont, Head of Corporate Strategy and Business Development at Grünenthal Group, a...
Biopharma Boardroom speaks with Nadia Aelbrecht, Vice President, Head of Infectious Disease at QIAGEN, about rapid diagnostics, antimicrobial...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
Symbiosis Pharmaceutical Services is entering a new phase of growth following a £26 million investment to expand its ...
As biologics and novel modalities become increasingly sophisticated, understanding molecular structure under controlled conditions tells only part ...
© 2026 Biopharma Boardroom. All Rights Reserved.